Analisis Resistensi Bakteri terhadap Antibiotik pada Pasien dengan Berbagai Golongan Darah
DOI:
https://doi.org/10.59841/jumkes.v3i4.3212Keywords:
Acinetobacter Baumannii, Antibiotic Therapy, Blood Type, Multidrug Resistance, Nosocomial InfectionAbstract
Acinetobacter baumannii is a major pathogenic bacterium causing nosocomial infections, known to exhibit high levels of resistance to various antibiotic classes, including β-lactams and aminoglycosides. This widespread resistance poses a significant challenge in hospital patient management, particularly in cases of severe and difficult-to-treat infections. This study aimed to analyze the resistance patterns of A. baumannii to four types of antibiotics in patients with various blood types at Dr. Soeradji Tirtonegoro General Hospital, Klaten. The research method used was a qualitative approach with a case study design. Data were obtained through in-depth interviews with healthcare workers, analysis of patient medical records, and limited observation of clinical practice. The focus of the study was directed at the relationship between patient blood type and the level of antibiotic resistance of A. baumannii. The results showed variations in resistance patterns based on blood type. Patients with blood type AB showed the highest level of resistance to all tested antibiotics, with a prevalence of multidrug resistance (MDR) reaching 85%. In contrast, patients with blood type O showed the lowest resistance and the highest proportion of non-MDR isolates compared to other groups. These findings indicate the role of host factors, namely blood type, in influencing the level of resistance of A. baumannii. The suspected mechanisms involved include differences in surface antigens that influence bacterial adhesion, biofilm formation, and the host immune response. The practical implication of this study is the need to consider blood type as a factor in empirical antibiotic therapy, especially in cases of nosocomial infections caused by A. baumannii.
References
Atasoy, A. R., Ciftci, I. H., & Petek, M. (2015). Modifying enzymes related aminoglycoside: Analyses of resistant Acinetobacter isolates. International Journal of Clinical and Experimental Medicine, 8(2), 2874.
Bidayah, H. F., Pratiwi, R., & Triyono, T. (2025). Dinamika golongan darah sistem ABO: Pendekatan seluler hingga molekuler. UGM Press. https://books.google.com/books?hl=id&lr=&id=MAtfEQAAQBAJ
Emu, M. R. K. (2024). Hubungan peningkatan penggunaan antibiotik dengan peningkatan resistensi bakteri Acinetobacter baumannii terhadap antibiotik [PhD thesis, Universitas Mahasaraswati Denpasar]. http://eprints.unmas.ac.id/id/eprint/6792/
Gentile, L. F., Nacionales, D. C., Lopez, M. C., Vanzant, E., Cuenca, A., Cuenca, A. G., Ungaro, R., Szpila, B. E., Larson, S., & Joseph, A. (2014). Protective immunity and defects in the neonatal and elderly immune response to sepsis. The Journal of Immunology, 192(7), 3156–3165. https://doi.org/10.4049/jimmunol.1301726
McMullan, B. J., Andresen, D., Blyth, C. C., Avent, M. L., Bowen, A. C., Britton, P. N., Clark, J. E., Cooper, C. M., Curtis, N., & Goeman, E. (2016). Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: Systematic review and guidelines. The Lancet Infectious Diseases, 16(8), e139–e152. https://doi.org/10.1016/S1473-3099(16)30024-X
Morfin-Otero, R., & Dowzicky, M. J. (2012). Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009. Clinical Therapeutics, 34(1), 101–112. https://doi.org/10.1016/j.clinthera.2011.11.028
Pratiwi, A. R., & Putri, D. K. T. (2022). Biofilm oral dan implikasi klinis pada rongga mulut. Universitas Brawijaya Press. https://books.google.com/books?hl=id&lr=&id=qGmSEAAAQBAJ
Puspitasari, I., & Asdie, R. H. (2025). Prinsip dan praktik penggunaan antimikroba. UGM Press. https://books.google.com/books?hl=id&lr=&id=VW1pEQAAQBAJ
Ramirez, M. S., & Tolmasky, M. E. (2017). Amikacin: Uses, resistance, and prospects for inhibition. Molecules, 22(12), 2267. https://doi.org/10.3390/molecules22122267
Regazzi, M., Berardi, A., Picone, S., & Tzialla, C. (2023). Pharmacokinetic and pharmacodynamic considerations of antibiotic use in neonates. Antibiotics, 12(12), 1747. https://doi.org/10.3390/antibiotics12121747
Sagita Putri, U. (2024). Profil resistensi Acinetobacter baumanii penghasil metallo beta-lactamase (MBL) terhadap antibiotik golongan karbapenem secara fenotip dan genotip di RSUP Dr. Wahidin Sudirohusodo [PhD thesis, Universitas Hasanuddin]. https://repository.unhas.ac.id/id/eprint/35427/
Simon, A. K., Hollander, G. A., & McMichael, A. (2015). Evolution of the immune system in humans from infancy to old age. Proceedings of the Royal Society B: Biological Sciences, 282(1821), 20143085. https://doi.org/10.1098/rspb.2014.3085
Tjoa, E., Moehario, L. H., Rukmana, A., & Rohsiswatmo, R. (2013). Acinetobacter baumannii: Role in bloodstream infection in neonatal unit, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia. International Journal of Microbiology, 2013, 180763. https://doi.org/10.1155/2013/180763
Ventola, C. L. (2015). The antibiotic resistance crisis: Part 1: Causes and threats. Pharmacy and Therapeutics, 40(4), 277–283.
Ventura, M. T., Casciaro, M., Gangemi, S., & Buquicchio, R. (2017). Immunosenescence in aging: Between immune cells depletion and cytokines up-regulation. Clinical and Molecular Allergy, 15(1), 21. https://doi.org/10.1186/s12948-017-0077-0
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Jurnal Mahasiswa Ilmu Kesehatan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
